ClinicalTrials.gg
CompletedNCT00367237Updated Apr 11, 2017Results posted

Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)

A Phase 3 interventional study of Infliximab + methotrexate (IFX + MTX) and Methotrexate (MTX) in Arthritis, Psoriatic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing methotrexate in Arthritis, Psoriatic — 5 open to participants now, 5 under way, 1 of them phase 3. Methotrexate · Arthritis, Psoriatic.

Enrollment
5th of 10
115 · median 112
Started
2006
the only one that year
Phase 3
4 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
1 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing methotrexate in Arthritis, Psoriatic, this one is the 5th largest by enrollment, is the only one that started in 2006, is one of 4 in phase 3, and was the 2nd registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 10 studies testing methotrexate in Arthritis, Psoriatic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 52 (59%) set no upper age limit and 27 (31%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing methotrexate in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This study is undertaken to compare the efficacy and onset of action of infliximab plus methotrexate (IFX + MTX) versus methotrexate alone (MTX) in methotrexate naïve active psoriatic arthritis patients.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must meet ALL of the criteria listed below for entry into the study:
  • Subject must demonstrate their willingness to participate in the study and comply with its procedures by signing a written .
  • Subject aged 18 years or more, of either sex and any race
  • Diagnosis of Psoriatic Arthritis with peripheral polyarticular involvement. Patients will have at least one of the following:

    • Distal Interphalangeal Joints (DIP) involvement
    • polyarticular arthritis, absence of rheumatoid nodules and presence of psoriasis
    • arthritis mutilans
    • asymmetric peripheral arthritis
  • Negative rheumatoid factor
  • The disease should have been diagnosed at least 3 months prior to screening.
  • Active disease at the time of screening and prior to receiving the baseline study medication(s) as defined by:

    • 5 or more swollen joints and
    • 5 or more tender joints
    • and one out of the following three categories:

      • Erythrocyte Sedimentation Rate (ESR) >= 28 mm/h
      • C-reactive protein (CRP) >= 15 mg/l
      • Morning stiffness >= 45 min
  • Subjects must confirm that they are practicing adequate : Female subjects of (includes women who are less than 1 year and women who become sexually active during the study) must agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male and female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (e.g., hysterectomy or tubal ligation).
  • Female subjects of childbearing potential must have a negative pregnancy test at Screening.
  • Subjects must be eligible for anti-tumor necrosis factor (TNF) treatment according to applicable local guidelines. For all patients chest X-ray and skin test results must be available at baseline.
  • If using Nonsteroidal anti-inflammatory drugs (NSAIDs) or other than i.v., i.m. or i.a., the patient must be on a stable dose for four weeks prior screening (maximum dose up to 10mg/day of prednisone or its oral equivalent).
  • The screening laboratory tests must beet the following criteria:

    • >= 10 g/dl providing the low hemoglobin level is not due to other diseases than anemia of chronic inflammation.
    • white blood cell (WBC) >= 3500 / μl
    • Neutrophils >= 1500 / μl
    • >= 100 000/ μl
    • , alanine aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase \<= 1.5 x
    • Total \<= 1 x upper limit of normal
    • Serum creatinine \<= 1.5 mg/dl
  • Patient must be able to adhere to the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures.

Exclusion criteria

Exclusion Criteria:

  • The subject will be excluded from entry into the study if ANY of the criteria listed below are met:
  • Subject is a female who is pregnant, intends to become pregnant during the study (or within 6 months after study completion), or nursing.
  • Patients with other inflammatory diseases that might interfere with the evaluation of the psoriatic arthritis.
  • Previous treatment with Infliximab.
  • Subjects who have previously received MTX or have not discontinued their other DMARD therapy (i.e., sulfasalazine, hydroxychloroquine, leflunomide).
  • Patients with fibromyalgia syndrome.
  • Use of cyclosporine or tacrolimus within 4 weeks prior to screening. Use of IM, IV, or IA within 4 weeks prior to screening.
  • Treatment with any drug within 3 months prior to screening.
  • Previous treatment with a monoclonal antibody or a fusion protein.
  • A history of known allergy to murine proteins.
  • History of infected joint prosthesis within the previous 5 years.
  • Chronic infections.
  • History of active tuberculosis requiring treatment within previous 3 years or history of opportunistic infections within 2 months, uncontrolled active infection or documented infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis without documented adequate therapy, if they will not be treated according to local tuberculosis (TB) guidelines.
  • Subject has any deviation from normal in the physical examination, chest X-ray, or (ECG) that, in the investigator's judgment, may interfere with the study evaluation or affect subject safety.
  • Current signs or symptoms of other severe uncontrolled diseases, which in the investigators opinion would put the patient at an unacceptable risk.
  • History of lymphoproliferative disease, any current or history of malignancy within 5 years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin.
  • Subject is part of the staff or a family member of the staff personnel directly involved with this study.
  • History of drug abuse.
  • Subjects who are participating in any other clinical study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Infliximab + methotrexate (IFX + MTX)

    Remicade (infliximab \[IFX\]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week

    Drug: Infliximab + methotrexate (IFX + MTX)

  • Active comparator
    Methotrexate (MTX)

    Oral methotrexate (MTX) 15 mg/week

    Drug: Methotrexate (MTX)

Interventions

  • DrugInfliximab + methotrexate (IFX + MTX)

    Drug pages: Infliximab · Methotrexate

    Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.

    Also known as: Group 1, Remicade + MTX

  • Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.

    Also known as: Group 2, MTX

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16

    \>=20% improvement in swollen and tender joint count AND \>=20% improvement in 3 of the following: visual analog scale (VAS) assessment of pain; subject VAS global assessment of disease activity; evaluator VAS global assessment of disease activity; Health Assessment Questionnaire (HAQ) disability index; C-Reactive Protein (CRP) level.

    Time frame: between baseline and week 16

Secondary outcomes

  1. Proportion of Subjects Achieving ACR50, ACR70, and PASI75 if Applicable

    This is not a prespecified key secondary outcome; therefore, results will not be disclosed.

    Time frame: between baseline and week 16

  2. Change in Disease Activity Score, Each of the ACR20 Domains, Dactylitis, Enthesitis, Fatigue and Duration of Morning Stiffness, Erythrocyte Sedimentation Rate, and Disability Index of the Health Assessment Questionnaire (HAQ)

    This is not a prespecified key secondary outcome; therefore, results will not be disclosed.

    Time frame: between baseline and week 16

  3. Adverse Events

    This is not a prespecified key secondary outcome; therefore, results will not be disclosed.

    Time frame: between baseline and week 16

07

Results

Posted Jul 7, 2009

Participant flow

115 subjects (57 infliximab (IFX) + MTX and 58 MTX), but only 110 subjects (56 and 54) were considered intent to treat (ITT). Furthermore, 99 subjects (51 + 48) were in a treatment group at Week 16 for Primary Endpoint evaluation.

Participant flow — Overall Study
MilestoneInfliximab + Methotrexate (IFX + MTX)Methotrexate (MTX)
Started5758
Completed4747
Not completed1011
Withdrew: Adverse event72
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject04
Withdrew: Protocol violation25

Outcome measures

PrimaryNumber of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16

\>=20% improvement in swollen and tender joint count AND \>=20% improvement in 3 of the following: visual analog scale (VAS) assessment of pain; subject VAS global assessment of disease activity; evaluator VAS global assessment of disease activity; Health Assessment Questionnaire (HAQ) disability index; C-Reactive Protein (CRP) level.

Time frame:
between baseline and week 16
Reported as:
Number · participants
Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16
participantsInfliximab + Methotrexate (IFX + MTX)Methotrexate (MTX)
Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 164432
Statistical analysis
  • Infliximab + Methotrexate (IFX + MTX) vs Methotrexate (MTX) · Chi-squared · p = 0.0210 (Comparison of treatments (IFX + MTX versus MTX)) · Difference in percentages of respondents: 19.61 · 95% CI 3.27 to 35.95Difference in percentages of respondents is (percentage of respondents in IFX+MTX group minus percentage of respondents in MTX group)
  • Infliximab + Methotrexate (IFX + MTX) · Proportion of responders: 0.863
  • Methotrexate (MTX) · Proportion of responders: 0.667
SecondaryProportion of Subjects Achieving ACR50, ACR70, and PASI75 if Applicable

This is not a prespecified key secondary outcome; therefore, results will not be disclosed.

Time frame:
between baseline and week 16

Results for this outcome have not been posted.

SecondaryChange in Disease Activity Score, Each of the ACR20 Domains, Dactylitis, Enthesitis, Fatigue and Duration of Morning Stiffness, Erythrocyte Sedimentation Rate, and Disability Index of the Health Assessment Questionnaire (HAQ)

This is not a prespecified key secondary outcome; therefore, results will not be disclosed.

Time frame:
between baseline and week 16

Results for this outcome have not been posted.

SecondaryAdverse Events

This is not a prespecified key secondary outcome; therefore, results will not be disclosed.

Time frame:
between baseline and week 16

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infliximab + Methotrexate (IFX + MTX)—2/57 (3.5%)12/57 (21.1%)
Methotrexate (MTX)—0/54 (0%)10/54 (18.5%)
Most frequent serious events
Most frequent serious events
EventInfliximab + Methotrexate (IFX + MTX)Methotrexate (MTX)
Infusion related reactionGeneral disorders1/570/54
Pulmonary TuberculosisInfections and infestations1/570/54
Most frequent other events
Most frequent other events
EventInfliximab + Methotrexate (IFX + MTX)Methotrexate (MTX)
Alanine Aminotransferase IncreasedInvestigations6/575/54
Abdominal Pain UpperGastrointestinal disorders0/573/54
Blood Bilirubin IncreasedInvestigations2/573/54
Transaminases IncreasedInvestigations3/571/54
HeadacheNervous system disorders3/571/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)Infliximab + Methotrexate (IFX + MTX)Methotrexate (MTX)Total
Mean40.1 (20 to 65)42.3 (21 to 65)41.2 (20 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Infliximab + Methotrexate (IFX + MTX)Methotrexate (MTX)Total
Female292150
Male273360
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Baranauskaite A, Raffayova H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N; RESPOND investigators. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012 Apr;71(4):541-8. doi: 10.1136/ard.2011.152223. Epub 2011 Oct 12. PubMed 21994233 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2006
First posted
Aug 22, 2006
Start
May 2006
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Jul 7, 2009
Last update
Apr 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00367237
Collaborators
Integrated Therapeutics Group
Responsible party
Sponsor
First posted
Aug 22, 2006
Start date
May 2006
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Jul 7, 2009
Last update
Apr 11, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Infliximab · Methotrexate

Start the discussion